Table 1.
Characteristics of studies included in meta-analysis
| Author and year | Journal | Country | Number of patient | Age (years) |
Follow-up (month) | Type of study | Outcome |
|---|---|---|---|---|---|---|---|
| Kai-Chi Cheng 202 2[26] | Transl Cancer Res | China | 130 | 63.60 ± 9.86 vs 65.48 ± 11.73 | 34(1–175) | RS | OS、RFS |
| S. Di Sandro 201 9[25] | Eur J Surg Oncol | Italy | 182 | 65(62–72) vs 65(56–76) | 33(17–56) | RS | OS、RFS |
| Satoshi Ogiso 202 1[24] | HPB | Japan | 221 | 69(46–88) vs 73(47–87) | 66(1–153) vs 57(1–130) | RS | OS、RFS |
| Yan-Hua Zhang 202 0[22] | World J Clin Cases | China | 175 | 63.5 ± 7.6 vs 62.8 ± 8.5 | 24 ± 6 | RS | OS、RFS |
| Dong Ho Lee 202 1[20] | Liver Cancer | Korea | 566 | 57.5 ± 9.3 vs 60.8 ± 9.6 | 30.0 ± 12.5 | RS | RFS |
| Chong LAI 201 6[21] | J Zhejiang Univ-Sci B | China | 94 | 56.5 ± 12.6 vs 62.8 ± 11.3 | 36 | RS | OS |
| Yang-xun Pan 202 0[23] | Eur J Surg Oncol | China | 477 | 51 (44–60) vs 57 (46–65) | 26.22(1.30–44.77) vs 24.20(0.97–44.73) | RS | OS、RFS |
| Juxian Song 201 5[27] | Surg Endosc | China | 156 | 48 (44–57) vs 48 (43–58) | 31.2(21.1–49.5) | RS | OS、RFS |
RS Retrospective study: OS Overall survival: RFS Recurrence-free survival.